Atlas Trials

Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC

Clinical trial NCT04338620 · UNKNOWN

Trial details

NCT number
NCT04338620
Sponsor
Tang-Du Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Non-small-cell Lung Cancer (NSCLC)
Start date
2020-04-07
Primary completion
2023-11-01
Enrollment
94

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.